SecBot SecBot

FTRE

Fortrea Holdings Inc.
Nasdaq· Services-Medical Laboratories· CIK 0001965040 Healthcare & Medical Devices
$23.88 +0.05 (+0.21%)
Oct 27 4:00 PM ET · prev $23.83
Market cap
$2.3B
Mid cap
Consensus
Buy
56% Buy or better · 18 analysts
Median target
$23.00
−4% · range $13.50–26.00
Next earnings
Oct 29
in 2 days
1 year
+129.8%
from $10.39 · Oct 27
30 days
+19.0%
from $20.06
52-week range
$8.87–24.06
−1% from high · low Mar 30
Avg volume 20D
1.75M
shares / day
Short interest
🔒 Subscribers only
Insider net
−$4.7M
0 buyers · 6 sellers · since Mar 6
New fund stakes
2
Q2 2026 13F · 0 exits
Filing reports
15
analyzed by SecBot
SecBot read BULLISH 13 reports · 90 days
Balance 0 bearish · 2 bullish · 3 mixed · 8 neutral oldest → newest, height = score
Avg score ·High conf. 9/13 ·Next Earnings date, Oct 29, 2026
Strongest BULLISH Fortrea completed the acquisition of Worldwide Clinical Trials' Early Phase Services division for ~$45M in…
All reports →

Price

Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.

Signal stack

Where each data set points today.

  • InsidersBEARISH

    6 insiders sold $4.7M.

  • InstitutionsMIXED

    Q2 2026: 27 added (2 new), 21 trimmed or exited. Largest new: Wellington Management Group $41.5M, Arrowstreet Capital, Limited Partnership $14.4M.

  • AnalystsBULLISH

    10 of 18 rate it Buy or better. Median target $23.00 (−4%).

  • TrendUPTREND

    20% above its 50-day average. New closing high $24.06 on Oct 21.

Who's buying

13F· Q2 2026
2
new positions
0
exits
$55.9M
in new stakes
FundMoveSharesValue
FMR LLCDOUBLED3,646,931$63.5M
Corvex Management LPTRIM2,988,551$52.0M
LOOMIS SAYLES & CO L PADD2,440,583$42.5M
WELLINGTON MANAGEMENT GROUP LLPNEW2,384,349$41.5M
DIMENSIONAL FUND ADVISORS LPADD1,650,100$28.7M
Nuveen, LLCADD1,421,943$24.7M
DEUTSCHE BANK AG\TRIM1,397,053$24.3M
Allianz Asset Management GmbHADD1,141,537$19.9M

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

18 analysts
Buy 56% rate it Buy or better
Strong Buy4Buy6Hold7Sell1Strong Sell0
12-month targets · 12 analysts

Price is inside the target range. Median implies −4%.Targets as of Oct 27, 2026.

Recent actions
DateFirmActionRating
Oct 20, 2026UBS
MAINTAIN
MAINTAINNeutral
Oct 15, 2026Deutsche Bank
UPGRADE
UPGRADEBuy
Oct 6, 2026Barclays
UPGRADE
UPGRADEOverweight
Sep 30, 2026UBS
INITIATE
INITIATENeutral
Aug 4, 2026TD Cowen
MAINTAIN
MAINTAINBuy
Jul 31, 2026Citigroup
MAINTAIN
MAINTAINBuy

Insider ledger

Form 4
$0
bought · 0 insiders
$4.7M
sold · 6 insiders
DateInsiderTypeValue
Sep 10, 2026
Knoblauch Jason Fredrick
Chief Financial Officer
AWARD144,434 sh
Sep 9, 2026
Morais Mark A.
Chief Operating Officer
SELL$53.1K
Sep 9, 2026
Russell Carrie Elizabeth
Interim CAO
SELL$4.1K
Sep 8, 2026
Morais Mark A.
Chief Operating Officer
EXERCISE7,157 sh
Sep 8, 2026
Russell Carrie Elizabeth
Interim CAO
EXERCISE850 sh
Aug 19, 2026
Morais Mark A.
Chief Operating Officer
SELL$89.0K
Aug 18, 2026
Morais Mark A.
Chief Operating Officer
EXERCISE11,313 sh
Aug 6, 2026
Thakral Anshul
Chief Executive Officer
SELL$1.0M

Earnings setup

Estimates
Oct 29
reports in 2 days

Revision history: 🔒 Fresh data, subscribers only

PeriodEPS est.Range30D rev.Revenue
Current Q🔒 Fresh data, subscribers only
Next Q🔒 Fresh data, subscribers only
Current FY🔒 Fresh data, subscribers only
Next FY🔒 Fresh data, subscribers only

Short side

FINRA· Oct 15, 2026
🔒 Subscribers only
shares short
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Oct 27, 2026 Press
🔒 Fresh report (last 24h), subscribers only
Oct 27, 2026 Contract
🔒 Fresh data, subscribers only
Oct 22, 2026 Press
Fortrea announced a collaboration with Omico, Australia's leading precision oncology screening organization, to…
Impact 3/10
Oct 5, 2026 SEC
Fortrea Holdings Inc announced it will report its Q3 2026 results on October 29, 2026.
PRESS-RELEASE — Impact 1/10
Sep 30, 2026 SEC
Fortrea Holdings Inc. appointed Carrie Russell as Chief Accounting Officer, effective October 5, 2026. Ms. Russell had…
8-K — Impact 2/10
Sep 10, 2026 SEC
Fortrea reinstated Jason Knoblauch as CFO after a Delaware Court of Chancery temporary restraining order was resolved…
8-K — Impact 3/10
Sep 10, 2026 Insider
Knoblauch Jason Fredrick was granted 144,434 shares
Chief Financial Officer
Sep 9, 2026 Insider
Morais Mark A. sold 3,149 shares
Chief Operating Officer @ $16.85 ($53.1K)
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
Upcoming
Oct 29, 2026
Earnings date
FTRE Q3 2026 Earnings Before Market Open — 2026-10-29
Recent
Oct 27, 2026
Contract
🔒 Fresh data, subscribers only
Oct 22, 2026
Contract
Fortrea and Omico Collaboration to Advance Biomarker-led Oncology Drug Development
Collaboration aims to improve trial planning and expand patient access to biomarker-matched studies in Australia...
Oct 19, 2026
M&A
Fortrea Completes Acquisition of the Early Phase Services Division from Worldwide Clinical Trials
Expands Fortrea’s early clinical development network with dedicated bioanalytical capabilities, increased clinical research unit capacity and a…
Oct 15, 2026
Short interest
🔒 Fresh data, subscribers only
Oct 5, 2026
Earnings
Fortrea Announces Date for Third Quarter 2026 Financial Results and Conference Call
DURHAM, N.C., Oct. 05, 2026 (GLOBE NEWSWIRE) -- Fortrea (Nasdaq: FTRE) (the “Company”), a leading global contract research organization (“CRO”)…

SecBot reports

15 filings · 7 press releases · 0 bullish · 1 bearish · 5 mixed · 9 neutral
All FTRE filing & press-release reports (22)